Antengene announces its u.s. partner, karyopharm therapeutics inc., has received fda approval of xpovio® (selinexor) as a treatment for patients with multiple myeloma after at least one prior therapy

Shanghai and hong kong, dec. 20, 2020 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk) today announced that the u.s. food and drug administration (fda) has approved the supplemental new drug application (snda) submitted by its partner karyopharm therapeutics inc....
KPTI Ratings Summary
KPTI Quant Ranking